ArcticZymes Joins MabDesign network to Strengthen Commercial Collaboration Across the European Bioprocessing Ecosystem

Oct 1, 2026

ArcticZymes Technologies is pleased to announce its membership in MabDesign, a leading European consortium supporting innovation and collaboration across the biopharmaceutical and advanced therapies sectors.

Through this membership, ArcticZymes joins a network of therapy developers, technology providers, CDMOs, research organizations, and manufacturing experts working together to address the evolving challenges of biomanufacturing. The network provides valuable opportunities for knowledge exchange, partnership development, and commercial collaboration across the advanced therapies value chain.

By strengthening its presence within leading industry networks, ArcticZymes continues to expand opportunities for scientific and commercial collaboration, reinforcing its commitment to enabling robust and scalable biomanufacturing solutions for advanced therapies.

‍

ArcticZymes Technologies Delivers 19% Sales Growth (29% CER) and NOK 7.4 Million EBITDA in Q2 2026 

Aug 14, 2026

Tromsø, Norway, 14 August 2026 – ArcticZymes Technologies ASA (OSE: AZT) today reported results for the second quarter and first half of 2026. Second-quarter sales revenue rose 19% year-on-year to NOK 31.9 million, or 29% at constant exchange rates (CER), while EBITDA increased 90% to NOK 7.4 million. For the first half, sales revenue grew 27% to NOK 63.7 million (39% CER) and EBITDA reached NOK 9.0 million, against break-even in the same period last year.

ArcticZymes Technologies Strengthens Board with Appointment of Dr. Hanna Pirita Lesch

May 28, 2026

Tromsø, Norway – 28 May 2026 – ArcticZymes Technologies ASA (OSE: AZT) today announced that, following approval at its Annual General Meeting, Dr. Hanna Pirita Lesch has been elected to the Company’s Board of Directors. Dr. Frank Mathias has been re-elected as Chair, and Petter Dragesund has been re-elected as a Board member. Sharon Brownlow steps down from the Board after a period of valued service.

ArcticZymes Technologies ASA: Notice of Annual General Meeting 2026

May 7, 2026

The annual general meeting ("AGM") for ArcticZymes Technologies ASA will be held on Thursday 28. May 2026 at 12.00 CET. The meeting will be held as a physical meeting, with an option for shareholders to participate digitally.

ArcticZymes Technologies Delivers 36% Sales Growth in Q1 2026, with Molecular Tools Rebound and Biomanufacturing Momentum

May 7, 2026

Tromsø, Norway, May 7, 2026 – ArcticZymes Technologies ASA (OSE: AZT) today reported first-quarter 2026 results, with sales up 36% year-on-year to NOK 31.8 million and positive EBITDA — a NOK 5.3 million turnaround versus Q1 2025. Growth was broad-based across both business segments, with Molecular Tools rebounding sharply and Biomanufacturing extending its commercial reach among global CDMOs.

ArcticZymes Technologies strengthens IP platform with new patent grant supporting expansion into RNA therapeutics manufacturing

Apr 30, 2026

ArcticZymes today announced the grant of a new patent supporting proprietary RNA restriction enzyme technologies for use within the therapeutic RNA manufacturing workflow, supporting the Company’s strategic expansion into the rapidly growing RNA therapeutics manufacturing market.

ArcticZymes Expands acib Collaboration and Joins CAARE Consortium to Advance Viral Vector Bioprocessing

Apr 28, 2026

ArcticZymes Technologies today announced its participation as an associated partner in the CAARE (Consortium for Advanced Analytical and Recovery Engineering) project, alongside an expansion of its ongoing research collaboration with the Austrian Centre of Industrial Biotechnology (acib), supported by additional funding through the COMET program.

ArcticZymes Technologies ASA Capital Markets Day 2026 [Video]

Mar 6, 2026

Watch ArcticZymes’ management team outline the strategy to scale and diversify its enzyme platform across biomanufacturing and molecular tools.

ArcticZymes Releases New White Paper Quantifying the Impact of Optimized Nuclease Strategy on Viral Vector Manufacturing Economics

Feb 26, 2026

Explore how different nucleases can significantly impact viral vector manufacturing yield, downstream process complexity and product purity in this new white paper. This innovative model is based upon published data, provides researcher and bioprocess engineers with a new insight into how small changes can have significant impacts resulting in lower costs per dose.

ArcticZymes Technologies Reports Strong Q4 and FY 2025 Results: Accelerating Sales Growth and Improved Profitability

Feb 12, 2026

Tromsø, Norway, February 12, 2026 – ArcticZymes Technologies ASA (OSE: AZT) today reported financial results for the fourth quarter and full year 2025, reflecting accelerating sales growth, improved operating leverage and continued penetration in its core business segments. Following a return to growth in 2025, the Company enters 2026 with strengthened commercial momentum and a robust balance sheet.

ArcticZymes Technologies Reports Q3 2025 Results: Continued Growth Momentum and Strengthened Profitability

Nov 6, 2025

Tromsø, Norway, November 6, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the third quarter of 2025, reporting strong topline growth and solid operational performance.

ArcticZymes ASA Appoints New Exclusive European Distributor for its Bioprocess Nuclease Range

Oct 29, 2025

ArcticZymes is pleased to announce a new, exclusive European distributor agreement with Brenntag Specialists Pharma to compliment its existing commercial team, supply the SAN-HQ and M-SAN HQ product lines.

ArcticZymes Technologies Reports Q2 and H1 2025 Results: Biomanufacturing Growth Accelerates as Customer centric Strategy Gains Momentum

Aug 14, 2025

Tromsø, Norway, August 14, 2025 – ArcticZymes Technologies (OSE: AZT) today announced its financial results for the second quarter of 2025, highlighting progress in the Company’s commercial transformation. Total revenues reached NOK 28.9 million, up 5% year-over-year, led by strong 52% growth in the Biomanufacturing segment which contributed NOK 18.1 million. The quarter also marked a strategic milestone with the on-time launch of GMP-grade M-SAN HQ, a product developed in direct response to customer needs. M-SAN HQ GMP enables broader integration into viral vector manufacturing and reinforces ArcticZymes’ role as a reliable partner in gene therapy workflows.

ArcticZymes Technologies Launches GMP-Grade Nuclease for Next-Generation Viral Vector Manufacturing.

Jun 16, 2025

We are pleased to announce the expansion of our GMP product range, with the introduction of M-SAN HQ GMP, a new GMP grade nuclease specifically designed for viral vector manufacturing.

Collaborative Research on use of Salt-Active Nucleases for Bionanoparticle Purification

ArcticZymes and Austrian Centre of Industrial Biotechnology Extend Collaborative Research on use of Salt-Active Nucleases for Bionanoparticle Purification

May 27, 2025

ArcticZymes Technologies ASA (OSE: AZT), in collaboration with the Austrian Centre of Industrial Biotechnology (acib), has extended their joint research partnership for another three years.

Notice of Annual General Meeting 2025

May 6, 2025

The annual general meeting (“AGM”) in ArcticZymes Technologies ASA will be held on Wednesday, May 27th, 2025 at 12.00 CET. The meeting will be held as a physical meeting at company premises at Siva Science Park, Tromsø. There will be an option for shareholders to participate digitally

ArcticZymes Technologies ASA Q4 2024 Results & Presentation

Feb 13, 2025

Tromsø, Norway, February 13th, 2025 – ArcticZymes Technologies (OSE: AZT) reported total revenues of NOK 26.4 million and an EBITDA of NOK 2.7 million for the fourth quarter of 2024.

ArcticZymes Expands SAN HQ Portfolio with Two Advanced Solutions Tailored for Cell, Gene and Vaccine Biomanufacturers

Dec 9, 2024

Tromsø, Norway – December 9, 2024 – ArcticZymes Technologies ASA (OSE: AZT) ArcticZymes introduces two cutting-edge products, SAN HQ ELISA SensoPlus and SAN HQ GMP neo, designed specifically to meet the evolving demands of the cell, gene and vaccine biomanufacturing sector.

ArcticZymes' M-SAN HQ Sets New Standard for Measles Virus Purification with Unmatched DNA Clearance & High Recovery Rates

Nov 21, 2024

Tromsø, Norway – November 21, 2024 – ArcticZymes Technologies ASA (OSE: AZT), is proud to highlight the exceptional performance of our M-SAN HQ nuclease in the purification of recombinant measles viruses (MV), as detailed in a recent publication in the Journal of Chromatography A.

ArcticZymes Technologies Announces Commercial Strategic Transformation and Q3 2024 Financial Results

Nov 6, 2024

Tromsø, Norway, November 6th, 2024 – ArcticZymes Technologies (OSE: AZT) reported revenues of NOK 24.1 million and an EBITDA of NOK -2.3 million for the third quarter of 2024.

ArcticZymes Highlights Industry-Leading Success at ESGCT 2024

Oct 24, 2024

ArcticZymes Technologies ASA (OSE: AZT), a global leader in enzyme innovation for bioprocessing, is excited to unveil breakthrough developments presented at the prestigious European Society of Gene and Cell Therapy (ESGCT) 2024 conference

ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing

Sep 17, 2024

ArcticZymes Leverages Rising Interest in Salt-Active Nucleases with New Whitepaper on Advancing Viral Vector Manufacturing

Research Paper About Novel RNA Restriction Enzyme Published in Journal: Nucleic Acids Research

Sep 16, 2024

ArcticZymes Technologies ASA Publishes Innovative Research on Novel RNA Restriction Enzyme, Paving the Way for Precision RNA Manipulation

ArcticZymes Technologies Q2 and 6M 2024 Results – Progress in partnership discussions and portfolio development

Aug 22, 2024

Tromsø, Norway, Aug 22, 2024 – ArcticZymes Technologies (OSE: AZT) reported revenues of NOK 27.5 million and an EBITDA of NOK 2.6 million for the second quarter of 2024.

Announcement of New Chairman and Board Members

Jun 27, 2024

Tromsø, Norway, June 27th, 2024—ArcticZymes Technologies (OSE: AZT) Announces Announces New Chairman and Board Members

Nomination of Dr. Frank Mathias as Chairman of the Board

Jun 25, 2024

Tromsø, Norway, June 25th, 2024—ArcticZymes Technologies (OSE: AZT) Announces Nomination of Dr. Frank Mathias as Chairman of the Board

Notice of Annual General Meeting 2024

Jun 5, 2024

The annual general meeting (“AGM”) in ArcticZymes Technologies ASA will be held on Wednesday, June 26th, 2024, at 15.00 CET.

ArcticZymes Technologies Changes to the Board of Directors

May 13, 2024

Tromsø, Norway, May 13th, 2024—ArcticZymes Technologies (OSE: AZT) announces Nominations for new Board members and the resignations of the Chairman and a Board member.

Presentation of Q1 2024 Results

May 8, 2024

Tromsø, Norway, May 8th, 2024 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 30.0 million and an EBITDA of NOK 2.3 million for the first quarter of 2024.

Joint Research with Austrian Centre of Industrial Biotechnology

Apr 9, 2024

Tromsø, Norway, April 9, 2024 - ArcticZymes Technologies ASA (OSE: AZT) and the Austrian Centre of Industrial Biotechnology (acib) enter a joint research project to uncover the benefits of salt active nucleases in the purification of bionanoparticles (BNP’s).

Research Paper on ArcticZymes R2D Ligase Published in the Biotechnology Journal

Mar 27, 2024

Tromsø, Norway, March 27, 2024 - ArcticZymes Technologies ASA (OSE: AZT) Research Paper on ArcticZymes R2D Ligase™ is published in the Biotechnology Journal

ArcticZymes Technologies ASA Q4 2023 Results & Presentation

Feb 1, 2024

Tromsø, Norway, February 1st, 2024 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.4 million and an EBITDA of NOK 2.0 million for the fourth quarter of 2023.

New Product Launch - SAN HQ GMP

Jan 30, 2024

Tromsø, Norway, January 30th, 2024 – ArcticZymes Technologies ASA (OSE:AZT) announces the launch of Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP).

ArcticZymes Technologies launches T7 RNA Polymerase

Dec 21, 2023

Tromsø, Norway, December 21, 2023 – ArcticZymes Technologies ASA (OSE: AZT) announced the launch of its new product, T7 RNA Polymerase. The T7 RNA Polymerase, specifically designed for molecular research and diagnostics, caters to the specialized needs of our customers in the Molecular Tools segment.

ArcticZymes Technologies Announces Partnership with Biomatter

Dec 19, 2023

Tromsø, Norway, December 19, 2023 – ArcticZymes Technologies ASA (OSE: AZT) enters an agreement with Biomatter (Biomatter Designs UAB) to develop new enzyme-based products.

ArcticZymes launches new website - Improved product info & customer experience

Dec 1, 2023

Tromsø, Norway, December 1st, 2023 - ArcticZymes Technologies ASA (OSE:AZT) announces the launch of its innovative new website with enhanced user ...

Long-Term Incentive Plan – share option grant to primary insider

Nov 3, 2023

Tromsø, Norway, November 3rd, 2023 – ArcticZymes Technologies ASA (OSE:AZT) The Board of Directors in ArcticZymes Technologies ASA has decided to grant 200.000 share options...

ArcticZymes Technologies ASA Q3 2023 results & presentation

Nov 2, 2023

Tromsø, Norway, November 2nd, 2023 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 31.2 million and an EBITDA of NOK 7.3 million for the third quarter of 2023. Highlights from Q3 and 9 months 2023 ArcticZymes Technologies (AZT) had Q3 sales of NOK 31.2 million (Q3 2022: NOK 29.3 million) and sales for the first 9 months of NOK …

DMF for SAN HQ GMP accepted by the US FDA

Sep 21, 2023

Tromsø, Norway, September 21st, 2023 – ArcticZymes Technologies ASA (OSE:AZT) announces that Salt Active Nuclease High Quality GMP grade (SAN HQ GMP) has passed the DMF filing Type II with the US Food and Drug Administration (FDA) and has received the acknowledgement letter with the Master File number 29754 as a reference. This means that ArcticZymes can provide its customers …

ArcticZymes Technologies ASA Q2 and 6 months 2023 results

Aug 17, 2023

Tromsø, Norway, August 17th, 2023 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.2 million and an EBITDA of NOK 6.8 million for the second quarter of 2023. Highlights from Q2 and 6 months 2023 ArcticZymes Technologies (AZT) had Q2 sales of NOK 28.2 million (Q2 2022: NOK 30.4 million) and sales for the first 6 months of NOK …

ArcticZymes Technologies launches SAN HQ 2.0 ELISA Kit

ArcticZymes Technologies is pleased to announce the launch of our newest product, the SAN HQ 2.0 ELISA kit. This classic sandwich ELISA is designed for the detection and quantification of SAN HQ 2.0 enzyme in samples taken from the manufacturing stages of a complex biomanufacturing process such as the production of viral vectors. The SAN HQ 2.0 ELISA Kit is

ArcticZymes Technologies releases its first ESG report

Dec 30, 2022

Tromsø, Norway, 30st December 2022 – ArcticZymes Technologies ASA (OSE: AZT) releases its first comprehensive ESG report ArcticZymes Technologies has today released its first comprehnesive Environment, Social and Governane (ESG) report based on data for the year 2021. The report is prepared in accordance with the framework established by the Global Reporting Initiative (GRI) and the Sustainability Accounting Standards Board

ArcticZymes Technologies Q4, full year 2022 results and extended investor presentation

Feb 2, 2023

Tromsø, Norway, 2th February 2022 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.2 million (40.5) and an EBITDA of NOK 1.3 million (20.8) for the fourth quarter of 2022. Highlights from Q4 and the full year 2022 ArcticZymes Technologies (AZT) had Q4 sales of NOK 28.2 million a reduction of 30% (Q4 2021: NOK 40.5 million) and sales

ArcticZymes Technologies announces CEO resignation

Mar 22, 2023

Tromso, March 22nd 2023 – ArcticZymes Technologies ASA (OSE: AZT) announces that the Board of Directors has today accepted the voluntary resignation of Jethro Holter as Chief Executive Officer, due to personal reasons. The resignation will take effect on 30th September 2023 after the required 6 months notice period. “On behalf of the Board, I want to thank Jethro very

ArcticZymes Technologies launches ArcticZymes Proteinase HQ

Apr 18, 2023

Tromsø, Norway, April 18nd 2023 – ArcticZymes Technologies ASA (OSE:AZT) announces the launch of ArcticZymes Proteinase HQ to the B2B market. Following up on earlier press-releases (9th Dec 2022) ArcticZymes is pleased to launch the latest member in our Proteinase product portfolio: ArcticZymes Proteinase HQ. This product is the ‘bioprocessing grade’ version of our existing successful ArcticZymes Proteinase and will be

Q1 2023 Results and presentation

May 3, 2023

Tromsø, Norway, 03rd May 2023 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 31.2 million and an EBITDA of NOK 6.1 million for the first quarter of 2023. Highlights from Q1 2023 ArcticZymes Technologies (AZT) had Q1 sales of NOK 31.2 million (Q1 2022: NOK 49.2 million, NOK 35.2 million adjusted for Covid effects in Q1 2022) AZT had

Notice of Annual General Meeting 2023

Aug 6, 2023

The annual general meeting (“AGM”) in ArcticZymes Technologies ASA will be held on Tuesday 06. June 2023 at 12.00 CET. The meeting will be held as a virtual meeting, with an option for shareholders to participate digitally. Please click HERE for the notice and appendicies Shareholders who wish to attend the AGM, in person, electronically or by proxy, are requested to

ArcticZymes Technologies has filed DMF for SAN HQ GMP

Jun 29, 2023

Tromsø, Norway, June 29th 2023 – ArcticZymes Technologies ASA (OSE:AZT) announces the filing of a Drug Master File (DMF) to the US Food and Drug Administration (FDA) for Salt Active Nuclease High Quality GMP Grade (SAN HQ GMP). ArcticZymes is pleased to announce the filing of a DMF (Type II) for SAN HQ GMP with the US FDA’s Center for

ArcticZymes Technologies launches AZtaq™ DNA Polymerase

Aug 10, 2023

Tromsø, Norway, August 10th, 2023 – ArcticZymes Technologies ASA (OSE: AZT) launches AZtaq™ DNA Polymerase. ArcticZymes Technologies (AZT) today announces the launch of its new product, AZtaq™ DNA Polymerase. AZtaq™ is a high-quality thermostable DNA polymerase suitable for use in polymerase chain reaction (PCR) applications. Launching the AZtaq™ is a natural expansion of the Company’s molecular tools portfolio. Being an